BIVIW

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week announced that its Phase 2 long COVID trial evaluating bezisterim has achieved full enrollment, marking an important milestone for the biotechnology company as it advances a potential treatment for patients suffering persistent post-COVID...

BioVie CEO Cuong Do joined Steve Darling from Proactive to announce the successful completion of patient enrollment for the company’s ADDRESS-LC Phase 2 clinical study evaluating its drug candidate bezisterim for the treatment of neurological symptoms associated with Long COVID. The study marks an important milestone for the company and is fully funded through a grant from the U.S. Department of Defense, helping advance the program without additional financing pressures tied directly to the trial. Do highlighted the growing healthcare challenge posed by Long COVID, which continues to affect millions of individuals long after their initial infection. According to estimates, approximately 15 million adults in the United States reported experiencing Long COVID between 2022 and 2023, with roughly 3.8 million indicating that symptoms significantly interfered with their daily activities and quality of life. The persistence of symptoms has created an increasing need for effective treatment options and greater clinical understanding of the condition. He explained that nearly half of individuals experiencing Long COVID develop symptoms that can persist either continuously or intermittently over extended periods. Among the most common and debilitating complications are neurological symptoms, which often include fatigue, cognitive impairment commonly referred to as “brain fog,” persistent cognitive dysfunction, post-exertional malaise, and sleep disturbances. These symptoms can create significant physical and emotional challenges for patients and have emerged as one of the major areas of focus in Long COVID research. BioVie noted that advancing scientific understanding continues to strengthen the rationale for bezisterim’s proposed mechanism of action. The company believes that growing evidence increasingly points to chronic inflammation and ongoing immune system activity as key contributors to many Long COVID symptoms, particularly those affecting neurological and neuropsychiatric function. Bezisterim is designed to target inflammatory pathways that may be driving these persistent symptoms. Despite growing awareness of Long COVID and increasing research efforts, treatment options remain limited. BioVie emphasized that there are currently no FDA-approved therapies specifically designed to treat Long COVID, leaving a significant unmet medical need and potentially creating a substantial opportunity for therapies capable of addressing the condition effectively. proactiveinvestors #biovieince #nasdaq #bivi #LongCOVID #ClinicalTrials #Biotech #DrugDevelopment #MedicalResearch #Neurology #HealthcareInnovation #Phase2Trial #Biopharma

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday it has completed enrollment in its ADDRESS-LC Phase 2 clinical trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID, with topline data expected later this summer. The trial, fully funded by a grant from the...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the last patient evaluation visit in its SUNRISE-PD Phase 2 clinical trial testing drug candidate bezisterim in early-stage Parkinson's disease, with topline results expected in the third quarter. The NASDAQ-listed clinical-stage company...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) has completed the last patient evaluation visit in its SUNRISE-PD Phase 2 clinical trial testing drug candidate bezisterim in early-stage Parkinson's disease, with topline results expected in the third quarter. The NASDAQ-listed clinical-stage company...

Last Patient Evaluation Visit Completed with Topline Data Release Targeted Q3-2026CARSON CITY, Nev., May 18, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last patient evaluation visit has been completed for the Company’s SUNRISE-PD Phase 2 trial evaluating its drug candidate bezisterim in early-stage Parkinson’s disease. “With

BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology May 7, 2026 2:00 PM EDTCompany...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined progress in its clinical program targeting long COVID, highlighting both the scale of the unmet need and the potential for a first-in-class treatment. In an interview with Proactive, CEO Cuong Do said that approximately 17...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined progress in its clinical program targeting long COVID, highlighting both the scale of the unmet need and the potential for a first-in-class treatment. In an interview with Proactive, CEO Cuong Do said that approximately 17...

BioVie CEO Cuong Do joined Steve Darling from Proactive to provide an update on the company’s ongoing clinical efforts targeting long COVID, a condition that continues to affect an estimated 17 million Americans despite the acute phase of the COVID-19 pandemic having subsided. Do emphasized that long COVID remains a significant and persistent public health challenge, with many patients experiencing debilitating symptoms such as brain fog, chronic fatigue, and general malaise that can severely impact daily functioning and quality of life. He noted that unlike the initial viral infection, long COVID appears to involve lingering viral protein fragments or related biological remnants that may continue to stimulate the immune system even after the virus has been cleared from the body. This ongoing immune activation is believed to contribute to sustained inflammation, which in turn may drive the neurological and systemic symptoms associated with the condition. BioVie Inc. is focusing its research efforts specifically on addressing these central nervous system-related symptoms through a targeted therapeutic approach. Do highlighted that the company’s program is supported by a $13 million clinical research grant, underscoring both the importance and urgency of developing effective treatments in this area. He also noted that BioVie is uniquely positioned in this space, stating that it is “the only company, nonprofit, any kind of organization to have received a grant to do this,” reinforcing the distinct nature of its clinical work. The company’s clinical trial is now nearing completion of patient enrollment, with top-line data expected by the end of the summer. This represents a key near-term milestone for the program as it moves toward evaluating efficacy and safety outcomes. Importantly, Do pointed out that there are currently no approved therapies specifically designed to treat long COVID, positioning BioVie’s program as a potential first-in-class treatment option in a space with significant unmet medical need. He expressed optimism about the trial’s progress and the potential impact of a successful outcome for patients who are still unable to return to normal daily activities or work due to lingering symptoms. proactiveinvestors #biovieince #nasdaq #bivi #LongCOVID #PostCOVID #ChronicFatigue #BrainFog #Neuroinflammation #ClinicalTrials #Biotech #CNSResearch #HealthcareInnovation #MedicalResearch #PublicHealth #Inflammation #DrugDevelopment #UnmetNeed

BioVie CEO Cuong Do joined Steve Darling from Proactive to provide an update on the company’s ongoing clinical efforts targeting long COVID, a condition that continues to affect an estimated 17 million Americans despite the acute phase of the COVID-19 pandemic having subsided. Do emphasized that long COVID remains a significant and persistent public health challenge, with many patients experiencing debilitating symptoms such as brain fog, chronic fatigue, and general malaise that can severely impact daily functioning and quality of life. He noted that unlike the initial viral infection, long COVID appears to involve lingering viral protein fragments or related biological remnants that may continue to stimulate the immune system even after the virus has been cleared from the body. This ongoing immune activation is believed to contribute to sustained inflammation, which in turn may drive the neurological and systemic symptoms associated with the condition. BioVie Inc. is focusing its research efforts specifically on addressing these central nervous system-related symptoms through a targeted therapeutic approach. Do highlighted that the company’s program is supported by a $13 million clinical research grant, underscoring both the importance and urgency of developing effective treatments in this area. He also noted that BioVie is uniquely positioned in this space, stating that it is “the only company, nonprofit, any kind of organization to have received a grant to do this,” reinforcing the distinct nature of its clinical work. The company’s clinical trial is now nearing completion of patient enrollment, with top-line data expected by the end of the summer. This represents a key near-term milestone for the program as it moves toward evaluating efficacy and safety outcomes. Importantly, Do pointed out that there are currently no approved therapies specifically designed to treat long COVID, positioning BioVie’s program as a potential first-in-class treatment option in a space with significant unmet medical need. He expressed optimism about the trial’s progress and the potential impact of a successful outcome for patients who are still unable to return to normal daily activities or work due to lingering symptoms. proactiveinvestors #biovieince #nasdaq #bivi #LongCOVID #PostCOVID #ChronicFatigue #BrainFog #Neuroinflammation #ClinicalTrials #Biotech #CNSResearch #HealthcareInnovation #MedicalResearch #PublicHealth #Inflammation #DrugDevelopment #UnmetNeed

CARSON CITY, Nev., April 27, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, May 7, 2026 at 2:00 PM ET featuring Suzanne de la Monte, MD, MPH (Brown University Warren Alpert Medical School, Providence VA Medical Center), who will join company management to discuss how

ORLANDO, FL / ACCESS Newswire / April 20, 2026 / RedChip Companies, an industry leader in investor relations, media, and research for microcap and small-cap companies, today announced that on-demand replays from its Biotech Resurgence: Platforms and ...

CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson’s Disease at the upcoming American Academy of Neurology Annual Meeting (AAN), to be held in Chicago, IL from April 18–22, 202

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday an abstract from its mid-stage study of experimental Parkinson’s disease treatment bezisterim has been accepted for presentation at an upcoming neurology conference. The abstract, based on the company’s SUNRISE-PD trial evaluating...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said on Tuesday an abstract from its mid-stage study of experimental Parkinson’s disease treatment bezisterim has been accepted for presentation at an upcoming neurology conference. The abstract, based on the company’s SUNRISE-PD trial evaluating...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined its evolving approach to Parkinson’s disease, with CEO Cuong Do highlighting the company’s focus on neuroinflammation and insulin resistance as key drivers of the condition. Speaking to Proactive, Do explained that while...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) earlier this week outlined its evolving approach to Parkinson’s disease, with CEO Cuong Do highlighting the company’s focus on neuroinflammation and insulin resistance as key drivers of the condition. Speaking to Proactive, Do explained that while...

BioVie CEO Cuong Do joined Steve Darling from Proactive to discuss the company’s novel approach to treating Parkinson’s disease, focusing on neuroinflammation and insulin resistance as key drivers of the condition. Do challenged the traditional view of Parkinson’s as solely a dopamine-related disorder, explaining that inflammation in the brain may play a more fundamental role. He noted that insulin resistance can impair the ability of brain cells to access glucose, stating, “If you have inflammation, the inflammation acts like rust on that lock… and therefore the door stays closed and glucose cannot get in.” This lack of energy in neurons may contribute significantly to disease progression. BioVie’s lead drug candidate, Bezisterim, is designed to target these underlying mechanisms. According to Do, clinical trials have shown that patients receiving the therapy experienced reductions in neuroinflammation along with improvements in insulin sensitivity. Earlier studies combining Bezisterim with Levodopa also demonstrated enhanced muscle control compared to standard treatment alone. The company is now advancing a new clinical trial evaluating Bezisterim as a standalone therapy in early-stage Parkinson’s patients. The study is designed to assess both motor and non-motor symptoms, including sleep, anxiety, and depression. With enrollment now complete, BioVie is targeting a topline data readout before the end of June, marking an important near-term catalyst for the program. proactiveinvestors #biovieince #nasdaq #bivi #NeurodegenerativeDiseases #parkinsonsdisease #BrainHealth #BioVie #CognitionImprovement #Neuroinflammation #SocialImpact #ElderlyCare #Neuroscience #HealthCrisis #DementiaSupport #BrainScience #GlobalHealth #InsulinResistance #Biotech #DrugDevelopment #ClinicalTrials #Bezisterim #CNSResearch #Neuroscience #HealthcareInnovation #MedicalResearch #Biopharma #Neurodegeneration #ToplineData

BioVie CEO Cuong Do joined Steve Darling from Proactive to discuss the company’s novel approach to treating Parkinson’s disease, focusing on neuroinflammation and insulin resistance as key drivers of the condition. Do challenged the traditional view of Parkinson’s as solely a dopamine-related disorder, explaining that inflammation in the brain may play a more fundamental role. He noted that insulin resistance can impair the ability of brain cells to access glucose, stating, “If you have inflammation, the inflammation acts like rust on that lock… and therefore the door stays closed and glucose cannot get in.” This lack of energy in neurons may contribute significantly to disease progression. BioVie’s lead drug candidate, Bezisterim, is designed to target these underlying mechanisms. According to Do, clinical trials have shown that patients receiving the therapy experienced reductions in neuroinflammation along with improvements in insulin sensitivity. Earlier studies combining Bezisterim with Levodopa also demonstrated enhanced muscle control compared to standard treatment alone. The company is now advancing a new clinical trial evaluating Bezisterim as a standalone therapy in early-stage Parkinson’s patients. The study is designed to assess both motor and non-motor symptoms, including sleep, anxiety, and depression. With enrollment now complete, BioVie is targeting a topline data readout before the end of June, marking an important near-term catalyst for the program. proactiveinvestors #biovieince #nasdaq #bivi #NeurodegenerativeDiseases #parkinsonsdisease #BrainHealth #BioVie #CognitionImprovement #Neuroinflammation #SocialImpact #ElderlyCare #Neuroscience #HealthCrisis #DementiaSupport #BrainScience #GlobalHealth #InsulinResistance #Biotech #DrugDevelopment #ClinicalTrials #Bezisterim #CNSResearch #Neuroscience #HealthcareInnovation #MedicalResearch #Biopharma #Neurodegeneration #ToplineData